London Vision Clinic Limited
Unaudited Financial Statements
For the year ended 31 December 2025
Pages for Filing with Registrar
Company Registration No. 04516362 (England and Wales)
London Vision Clinic Limited
Company Information
Director
Prof D Z Reinstein
Company number
04516362
Registered office
138 Harley Street
London
United Kingdom
WIG 7LA
Accountants
Moore Kingston Smith LLP
6th Floor
9 Appold Street
London
EC2A 2AP
London Vision Clinic Limited
Contents
Page
Balance sheet
1 - 2
Statement of changes in equity
3
Notes to the financial statements
4 - 12
London Vision Clinic Limited
Balance Sheet
As at 31 December 2025
Page 1
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
4
100,345
163,382
Tangible assets
5
55,593
67,082
Investment properties
6
8,130,000
8,130,000
8,285,938
8,360,464
Current assets
Debtors
7
377,792
417,165
Cash at bank and in hand
106,670
1,215,070
484,462
1,632,235
Creditors: amounts falling due within one year
9
(568,824)
(709,131)
Net current (liabilities)/assets
(84,362)
923,104
Total assets less current liabilities
8,201,576
9,283,568
Creditors: amounts falling due after more than one year
8
(3,488,194)
(3,617,653)
Net assets
4,713,382
5,665,915
Capital and reserves
Called up share capital
10
2
2
Revaluation reserve
796,793
1,116,498
Profit and loss reserves
3,916,587
4,549,415
Total equity
4,713,382
5,665,915
London Vision Clinic Limited
Balance Sheet (Continued)
As at 31 December 2025
Page 2

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and signed by the director and authorised for issue on 1 September 2026
Prof D Z Reinstein
Director
Company Registration No. 04516362
London Vision Clinic Limited
Statement of Changes in Equity
For the year ended 31 December 2025
Page 3
Share capital
Revaluation reserve
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 1 January 2024
2
1,116,498
3,738,083
4,854,583
Period ended 31 December 2024:
Profit and total comprehensive income for the year
-
-
901,332
901,332
Dividends
-
-
(90,000)
(90,000)
Balance at 31 December 2024
2
1,116,498
4,549,415
5,665,915
Period ended 31 December 2025:
Profit and total comprehensive income for the year
-
-
185,367
185,367
Dividends
-
-
(1,137,900)
(1,137,900)
Transfer from Profit and loss reserve
-
(319,705)
319,705
-
Balance at 31 December 2025
2
796,793
3,916,587
4,713,382
London Vision Clinic Limited
Notes to the Financial Statements
For the year ended 31 December 2025
Page 4
1
Accounting policies
Company information

London Vision Clinic Limited is a private company limited by shares incorporated in England and Wales. The registered office is 138 Harley Street, London, United Kingdom, WIG 7LA.

1.1
Accounting convention

These financial statements have been prepared in accordance with section 1A of FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2
Going concern

The financial statements are prepared on a going concern basis which assumes the company will continue in operational existence for the foreseeable future. The directors have considered the impact of thetrue general economic conditions in the UK and are satisfied the company can continue in operation for at least twelve months from the date of approval of the financial statements and accordingly the financial statements continue to be prepared on the going concern basis.

1.3
Turnover

Turnover represents amounts receivable as rental and consultancy services. Turnover is recognised at the fair value of the consideration received or receivable for rent and consultancy services, and is shown net of VAT and other sales related taxes.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

London Vision Clinic Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2025
1
Accounting policies
(Continued)
Page 5
1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Research expenditure is written off to the profit and loss account in the year in which it is incurred. Development expenditure is written off in the same way unless the director are satisfied as to the technical, commercial and financial viability of individual projects. In this situation, the expenditure is deferred and amortised over the period during which the company is expected to benefit.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Development Costs
Straight line over 5 years
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
Straight line over 10 years
Plant and machinery
Straight line over 5 years
Fixtures, fittings & equipment
Straight line over 5 years
Computer equipment
Straight line over 5 years
1.6
Investment properties

Investment property, which is property held to earn rentals and/or for capital appreciation, is initially recognised at cost, which includes the purchase cost and any directly attributable expenditure. Subsequently it is measured at fair value at the reporting end date. Changes in fair value are recognised in profit or loss.

1.7
Impairment of fixed assets

At each reporting end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

Intangible assets with indefinite useful lives and intangible assets not yet available for use are tested for impairment annually, and whenever there is an indication that the asset may be impaired.

London Vision Clinic Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2025
1
Accounting policies
(Continued)
Page 6

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

 

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried in at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.8
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

London Vision Clinic Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2025
1
Accounting policies
(Continued)
Page 7

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

Changes in the fair value of derivatives that are designated and qualify as fair value hedges are recognised in profit or loss immediately, together with any changes in the fair value of the hedged asset or liability that are attributable to the hedged risk.

1.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

London Vision Clinic Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2025
1
Accounting policies
(Continued)
Page 8
1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.14
Foreign exchange
Transactions denominated in foreign currencies are translated into sterling at the rate of exchange ruling at the date of the transaction. Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the end of the financial year.  All exchange differences are dealt with in the profit and loss account.
2
Employees

The company has average number of employees during the year.

2025
2024
Number
Number
Total
1
2
3
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
77,650
270,459
4
Intangible fixed assets
Development costs
£
Cost
At 1 January 2025 and 31 December 2025
687,536
Amortisation and impairment
At 1 January 2025
524,154
Amortisation charged for the year
63,037
At 31 December 2025
587,191
Carrying amount
At 31 December 2025
100,345
At 31 December 2024
163,382
London Vision Clinic Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2025
4
Intangible fixed assets
(Continued)
Page 9

The original project was completed in April 2018. The development costs are to be amortised over 5 years as this is believed to be the useful economic life of the asset. The additions during the year ended 31 December 2023 was for follow up work in connection to the initial project and costs in relation to a new project. No further additions were made in 2025 but the project remains incomplete.

5
Tangible fixed assets
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 1 January 2025
21,922
62,613
84,535
Additions
-
0
3,241
3,241
At 31 December 2025
21,922
65,854
87,776
Depreciation and impairment
At 1 January 2025
6,576
10,877
17,453
Depreciation charged in the year
2,192
12,538
14,730
At 31 December 2025
8,768
23,415
32,183
Carrying amount
At 31 December 2025
13,154
42,439
55,593
At 31 December 2024
15,346
51,736
67,082
6
Investment property
2025
£
Fair value
At 1 January 2025 and 31 December 2025
8,130,000

The fair value of the investment property had been originally arrived at on the basis of a valuation carried out at November 2023 by Chartered Surveyors, who are not connected with the company. The valuation was made on an open market value basis by reference to market evidence of transaction prices for similar properties.

 

At the year end, the director has reviewed the value of the investment property and based on his market knowledge he believed the fair value of the investment property should remain unchanged as at the professional valuation from November 2023.

 

London Vision Clinic Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2025
6
Investment property
(Continued)
Page 10
If investment properties were stated on an historical cost basis rather than a fair value basis, the amounts would have been included as follows:
2025
2024
£
£
Cost
7,724,812
7,724,812
Accumulated depreciation
(391,606)
(391,606)
Carrying amount
7,333,206
7,333,206
7
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
200,821
163,099
Other debtors
2,491
9,827
Prepayments and accrued income
174,480
244,239
377,792
417,165
8
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
3,488,194
3,617,653

The bank loan is due for repayment in full by 15 August 2035. Interest is charged at a rate of 2.5% (previously 2.3%) above the Lloyds Bank base rate.

 

The loan is secured by way of a fixed and floating charge over the assets of the company and an unlimited debenture from the company and London Vision Clinic Partners Limited (previously London Vision Clinic Associates LLP).

 

An omnibus guarantee and offset agreement exists among the bank, the company and London Vision Clinic Partners Limited.

London Vision Clinic Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2025
Page 11
9
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans
139,675
130,907
Trade creditors
207,452
14,539
Corporation tax
49,670
270,459
Other creditors
172,027
293,226
568,824
709,131
10
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary Shares of £1 each
2
2
2
2
London Vision Clinic Limited
Notes to the Financial Statements (Continued)
For the year ended 31 December 2025
Page 12
11
Related party transactions

No guarantees have been given or received.

 

The company invoiced a company that has a mutual director £330,000 (2024: £330,000) in respect of rent and service charges for the year.

12
Parent company

The company is controlled by Prof D Z Reinstein.

2025-12-312025-01-01falsefalsefalse11 September 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityProf D Z Reinstein2026-09-01045163622025-01-012025-12-3104516362bus:Director12025-01-012025-12-3104516362bus:RegisteredOffice2025-01-012025-12-31045163622025-12-31045163622024-12-3104516362core:IntangibleAssetsOtherThanGoodwill2025-12-3104516362core:IntangibleAssetsOtherThanGoodwill2024-12-3104516362core:LandBuildings2025-12-3104516362core:OtherPropertyPlantEquipment2025-12-3104516362core:LandBuildings2024-12-3104516362core:OtherPropertyPlantEquipment2024-12-3104516362core:CurrentFinancialInstruments2025-12-3104516362core:CurrentFinancialInstruments2024-12-3104516362core:Non-currentFinancialInstruments2025-12-3104516362core:Non-currentFinancialInstruments2024-12-3104516362core:ShareCapital2025-12-3104516362core:ShareCapital2024-12-3104516362core:RevaluationReserve2025-12-3104516362core:RevaluationReserve2024-12-3104516362core:RetainedEarningsAccumulatedLosses2025-12-3104516362core:RetainedEarningsAccumulatedLosses2024-12-3104516362core:ShareCapital2023-12-3104516362core:RevaluationReserve2023-12-3104516362core:RetainedEarningsAccumulatedLosses2023-12-3104516362core:ShareCapitalOrdinaryShareClass12025-12-3104516362core:ShareCapitalOrdinaryShareClass12024-12-31045163622024-01-012024-12-3104516362core:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3104516362core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-01-012025-12-3104516362core:PlantMachinery2025-01-012025-12-3104516362core:FurnitureFittings2025-01-012025-12-3104516362core:ComputerEquipment2025-01-012025-12-3104516362core:UKTax2025-01-012025-12-3104516362core:UKTax2024-01-012024-12-3104516362core:IntangibleAssetsOtherThanGoodwill2024-12-3104516362core:LandBuildings2024-12-3104516362core:OtherPropertyPlantEquipment2024-12-31045163622024-12-3104516362core:LandBuildings2025-01-012025-12-3104516362core:OtherPropertyPlantEquipment2025-01-012025-12-3104516362core:CurrentFinancialInstrumentscore:WithinOneYear2025-12-3104516362core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3104516362bus:OrdinaryShareClass12025-01-012025-12-3104516362bus:OrdinaryShareClass12025-12-3104516362bus:OrdinaryShareClass12024-12-3104516362bus:PrivateLimitedCompanyLtd2025-01-012025-12-3104516362bus:SmallCompaniesRegimeForAccounts2025-01-012025-12-3104516362bus:FRS1022025-01-012025-12-3104516362bus:AuditExemptWithAccountantsReport2025-01-012025-12-3104516362bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP